Skip to main content
. Author manuscript; available in PMC: 2022 Jan 9.
Published in final edited form as: Sci Immunol. 2021 Jul 9;6(61):eabi8472. doi: 10.1126/sciimmunol.abi8472

Fig. 3. Depleting lung TNFR2+ cDC2s rendered the IFNβ therapy ineffective.

Fig. 3.

(A) Experimental protocol for the depletion of TNFR2-expressing cells in asthmatic mice. (B) Flow cytometry analysis of TNFR2+ cDC2s in asthmatic mice treated with IFNβ/isotype control or IFNβ/anti-TNFR2 antibody (20 μg) (n = 3 mice per group). Data are representative of two independent experiments. (C) Total numbers of lung DC subsets in (B) (n = 3 mice per group). Data are representative of two independent experiments. (D) Flow cytometry analysis of Tregs in asthmatic mice treated with IFNβ (0.2 μg)/isotype control or IFNβ/anti-TNFR2 antibody (20 μg) (n = 3 mice per group). Data are representative of two independent experiments. (E) Serum levels of HDM-specific IgG1 in asthmatic mice treated with IFNβ/isotype control or IFNβ/anti-TNFR2 antibody (20 μg) (n = 3 mice per group). Data are representative of two independent experiments. Graphs represent the mean, with error bars indicating SEM. P values were determined by two-way ANOVA with Sidak’s multiple comparison test (C) or two-way ANOVA with Tukey’s multiple comparison test (E).